Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)
Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)
Active, not recruiting · NCT03896074 · Registry updated 2026-02-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) | Non-small-cell Lung Cancer Patients | Active, not recruiting | Phase 2 | 2026-02-09 | NCT03896074 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fondazione Ricerca Traslazionale | 7 |
33 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.